PD-013Final survival results of a multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer patients refractory to standard therapies (C-TASK FORCE)
2016
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI